Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy

CDK4 & 6 inhibitors have enhanced the effectiveness of endocrine therapy (ET) in patients with advanced breast cancer (ABC). This paper presents exploratory analyses examining patient and disease characteristics that may inform in whom and when abemaciclib should be initiated. MONARCH 2 and 3 en...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:NPJ Breast Cancer
Autors principals: Di Leo, Angelo, O’Shaughnessy, Joyce, Sledge, George W., Martin, Miguel, Lin, Yong, Frenzel, Martin, Hardebeck, Molly C., Smith, Ian C., Llombart-Cussac, Antonio, Goetz, Matthew P., Johnston, Stephen
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6299082/
https://ncbi.nlm.nih.gov/pubmed/30588487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-018-0094-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars